Elevated mepolizumab levels in patients with severe asthma responsive to 1 year’s mepolizumab treatment

Background: Asthma involves variable airflow limitation and persistent airway inflammation. Eosinophilic asthma, characterized by cytokine-mediated type 2 inflammation, is generally treated with inhaled corticosteroids. However, patients with severe asthma may require biologics, such as mepolizumab,...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Takayasu Nishimaki, MD, Hitoshi Sasano, MD, PhD, Sonoko Harada, PhD, Tomohito Takeshige, MD, PhD, Yuuki Sandhu, MD, PhD, Yuki Tanabe, MD, Kei Matsuno, MD, PhD, Tetsutaro Nagaoka, MD, PhD, Jun Ito, MD, PhD, Ryo Atsuta, MD, PhD, Mayu Ohuchi, PhD, Shigehiro Yagishita, MD, PhD, Akinobu Hamada, PhD, Kazuhisa Takahashi, MD, PhD, Norihiro Harada, MD, PhD
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Elsevier 2025-05-01
coleção:	Journal of Allergy and Clinical Immunology: Global
Assuntos:	Asthma mepolizumab concentration
Acesso em linha:	http://www.sciencedirect.com/science/article/pii/S2772829325000116
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!